Skip to content
Inciteful Med

Decoding Your Diagnosis: Tests and Reports

Last updated:

Diagnosing Autosomal Dominant Optic Atrophy (ADOA) relies on three main tests: OCT imaging to detect optic nerve thinning, visual field testing to find central blind spots, and genetic testing to identify OPA1 mutations. Understanding these reports helps you track your optic nerve health.

Key Takeaways

  • • OCT scans in ADOA typically reveal thinning in the macular ganglion cell complex and the temporal retinal nerve fiber layer.
  • • A classic visual sign of ADOA is a centrocecal scotoma, which is a blind spot in the center of your vision.
  • • Genetic testing for the OPA1 gene is the only way to definitively confirm an Autosomal Dominant Optic Atrophy diagnosis.
  • • If standard genetic testing is negative, specialized CNV or MLPA testing is needed to find larger, hidden OPA1 gene deletions.
  • • Initial eye scans and visual field tests serve as an essential baseline to monitor the slow progression of the condition.

Navigating the diagnostic process for Autosomal Dominant Optic Atrophy (ADOA) can feel like learning a new language. Your medical reports contain critical clues that help your care team differentiate ADOA from other conditions and monitor the health of your optic nerve.

The Structural Blueprint: OCT Imaging

Optical Coherence Tomography (OCT) is the most vital tool in your diagnostic toolkit. It is a non-invasive light scan that measures the thickness of the layers in the back of your eye [1][2].

  • GCC (Macular Ganglion Cell Complex): This measures the “bodies” of the nerve cells. In ADOA, doctors look for a very specific pattern: thinning that is most pronounced in the nasal (side closest to the nose) part of the inner macula [3][4].
  • RNFL (Retinal Nerve Fiber Layer): This measures the “cables” (axons) that form the optic nerve. ADOA typically causes significant thinning in the temporal (side closest to the ear) sector of the optic nerve [3][1].
  • The Baseline: Because ADOA is slow-moving, the first OCT is your “baseline.” Future scans will be compared to this one to see if the condition is stable [1].

The Functional Map: Visual Field Testing

While OCT looks at the structure, Visual Field Testing (often called a “Humphrey” test) looks at how you actually see.

  • Centrocecal Scotoma: This is the classic visual field finding in ADOA. It is a blind spot or blurry area that sits in the center of your vision and stretches toward the natural blind spot of the eye [5][1].
  • Monitoring Sensitivity: The test also measures your foveal sensitivity (how well you see in the dead center) and your contrast sensitivity, which help determine how the condition affects daily activities like reading [6][1].

The Genetic Confirmation

Genetic testing is the only way to be 100% certain of an ADOA diagnosis. The primary target is the OPA1 gene [7][8].

  • Point Mutations: Most tests start by “spelling” the gene to look for a single letter change.
  • The “Hidden” Deletions (CNV/MLPA): If standard testing is negative, it is crucial to ask for Copy Number Variation (CNV) testing, often done using a method called MLPA [9][10]. This looks for “missing chapters” (large deletions) or “extra pages” (duplications) in the OPA1 gene that standard spelling tests can miss [10][11].
  • Other Genes: In rare cases where OPA1 is normal, mutations in other genes like AFG3L2 or SPG7 can cause a similar presentation [12][8].

Checklist: What Should Be in Your Report?

Every comprehensive ADOA diagnostic report should include the following data points to ensure you have a complete picture of your health:

  1. Genetic Mutation: The specific OPA1 variant and whether it is a point mutation or a deletion [13][14].
  2. Inheritance Type: Whether the mutation was inherited from a parent (autosomal dominant) or occurred for the first time in the patient (de novo) [15][16]. To learn more about this, visit Subtypes & Genetics.
  3. OCT Measurements: Specific thickness numbers for the pRNFL and GCC [1][3].
  4. Visual Acuity and Color Results: Documentation of your BCVA (best-corrected visual acuity) and whether you have blue-yellow color deficits [5][13].
  5. Phenotype Classification: A clear statement on whether the presentation is Classic ADOA or ADOA-Plus [14][17].

Frequently Asked Questions

What does an OCT scan show for ADOA?
An Optical Coherence Tomography (OCT) scan is a non-invasive test that measures the thickness of the layers in the back of your eye. In ADOA, it typically shows specific thinning in the ganglion cell complex and the temporal sector of the retinal nerve fiber layer.
What is a centrocecal scotoma?
A centrocecal scotoma is a classic visual field finding in ADOA. It is a blind spot or area of blurry vision that sits in the center of your sight and stretches toward the eye's natural blind spot.
What if my standard OPA1 genetic test is negative but I have ADOA symptoms?
If standard point mutation testing is negative, your doctor may order a Copy Number Variation (CNV) or MLPA test to check for larger, hidden deletions in the OPA1 gene. If that is also negative, mutations in other genes like AFG3L2 or SPG7 could be the cause.
Why do I need baseline visual field and OCT tests?
Because ADOA progresses slowly over time, your first visual field and OCT tests serve as a baseline. Your care team will compare all future scans against these initial results to monitor any changes in your optic nerve health and central vision.

Questions for Your Doctor

  • • Does my OCT report show the specific 'nasal' thinning in the ganglion cell layer and 'temporal' thinning of the optic nerve fibers?
  • • Was my genetic testing limited to point mutations, or did it include a 'CNV' or 'MLPA' test to look for large deletions?
  • • If my OPA1 test was negative, should we expand the search to include other genes like AFG3L2 or SPG7?
  • • How do these results confirm this is ADOA and not a similar condition like Normal Tension Glaucoma?
  • • What is the current 'baseline' of my visual field, and how will you use this to monitor for changes in the centrocecal scotoma?

Questions for You

  • • Do you have a physical or digital copy of your genetic report and OCT scans to keep for your records?
  • • During your visual field test, did you find it harder to see the lights in the very center of your gaze compared to the sides?
  • • Have you noticed any subtle changes in your hearing or balance that should be mentioned in your diagnostic report?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Clinical and Structural Parameters in Autosomal Dominant Optic Atrophy Patients: A Cross-Sectional Study Using Optical Coherence Tomography.

    Camós-Carreras A, Figueras-Roca M, Albà-Arbalat S, et al.

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2024; (45(3)):273-277 doi:10.1097/WNO.0000000000002294.

    PMID: 39805076
  2. 2

    Comparison of the clinical and genetic features of autosomal dominant optic atrophy and normal tension glaucoma in young Chinese adults.

    Zhang Y, Sun X, Tian G, Chen Y

    Eye (London, England) 2023; (37(4)):624-630 doi:10.1038/s41433-022-01990-y.

    PMID: 35273349
  3. 3

    Thickness mapping of individual retinal layers and sectors by Spectralis SD-OCT in Autosomal Dominant Optic Atrophy.

    Corajevic N, Larsen M, Rönnbäck C

    Acta ophthalmologica 2018; (96(3)):251-256 doi:10.1111/aos.13588.

    PMID: 29091347
  4. 4

    Assessment of the retinal posterior pole in dominant optic atrophy by spectral-domain optical coherence tomography and microperimetry.

    Cesareo M, Ciuffoletti E, Martucci A, et al.

    PloS one 2017; (12(3)):e0174560 doi:10.1371/journal.pone.0174560.

    PMID: 28358911
  5. 5

    New avenues for therapy in mitochondrial optic neuropathies.

    Ng WSV, Trigano M, Freeman T, et al.

    Therapeutic advances in rare disease 2021; (2()):26330040211029037 doi:10.1177/26330040211029037.

    PMID: 37181108
  6. 6

    Optic Atrophy Predominant WFS1 Disorder-A Case-Control Study.

    Levergood NR, Ko MW, Payne KK, Mackay DD

    Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2025; doi:10.1097/WNO.0000000000002428.

    PMID: 41411089
  7. 7

    [Differential diagnosis of juvenile normal pressure glaucoma].

    Geidel K, Wiedemann P, Unterlauft JD

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2017; (114(9)):828-831 doi:10.1007/s00347-016-0407-5.

    PMID: 27921132
  8. 8

    Mutation Screening of mtDNA Combined Targeted Exon Sequencing in a Cohort With Suspected Hereditary Optic Neuropathy.

    Li JK, Li W, Gao FJ, et al.

    Translational vision science & technology 2020; (9(8)):11 doi:10.1167/tvst.9.8.11.

    PMID: 32855858
  9. 9

    Identification of copy number variation in the gene for autosomal dominant optic atrophy, OPA1, in a Chinese pedigree.

    Jin X, Chen YH, Liu Z, et al.

    Genetics and molecular research : GMR 2015; (14(3)):10961-72 doi:10.4238/2015.September.21.8.

    PMID: 26400325
  10. 10

    Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy: Identification and classification of 48 novel variants.

    Weisschuh N, Schimpf-Linzenbold S, Mazzola P, et al.

    PloS one 2021; (16(7)):e0253987 doi:10.1371/journal.pone.0253987.

    PMID: 34242285
  11. 11

    Characterization of two novel intronic OPA1 mutations resulting in aberrant pre-mRNA splicing.

    Bolognini R, Gerth-Kahlert C, Abegg M, et al.

    BMC medical genetics 2017; (18(1)):22 doi:10.1186/s12881-017-0383-x.

    PMID: 28245802
  12. 12

    A novel AFG3L2 mutation close to AAA domain leads to aberrant OMA1 and OPA1 processing in a family with optic atrophy.

    Baderna V, Schultz J, Kearns LS, et al.

    Acta neuropathologica communications 2020; (8(1)):93 doi:10.1186/s40478-020-00975-w.

    PMID: 32600459
  13. 13

    [Hereditary Optic Neuropathies].

    Rüther K

    Klinische Monatsblatter fur Augenheilkunde 2018; (235(6)):747-763 doi:10.1055/a-0583-6290.

    PMID: 29490390
  14. 14

    Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy.

    Ham M, Han J, Osann K, et al.

    Mitochondrion 2019; (46()):262-269 doi:10.1016/j.mito.2018.07.006.

    PMID: 30165240
  15. 15

    [Genetic Causes and Genetic Diagnostic Testing of Inherited Optic Atrophies].

    Wissinger B

    Klinische Monatsblatter fur Augenheilkunde 2018; (235(11)):1235-1241 doi:10.1055/a-0759-2094.

    PMID: 30458563
  16. 16

    IT TAKES TWO TO TANGO: potential novel therapies for autosomal dominant optic atrophy.

    Sampige R, Seaborn LEA, Pluenneke M, et al.

    Frontiers in ophthalmology 2025; (5()):1688232 doi:10.3389/fopht.2025.1688232.

    PMID: 41268195
  17. 17

    A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family.

    Ahmad KE, Davis RL, Sue CM

    Journal of neurology 2015; (262(10)):2323-8 doi:10.1007/s00415-015-7849-6.

    PMID: 26194196

This page explains ADOA diagnostic reports and testing for educational purposes only. Always consult your ophthalmologist or genetic counselor to interpret your specific eye scans and genetic results.

Stay up to date

Get notified when new research about Autosomal dominant optic atrophy, classic form is published.

No spam. Unsubscribe anytime.